tirzepatide and aod9604 AOD9604: A Dual Approach to Effective Weight Management - Semaglutide | Tirzepatide | Retatrutide Weight Loss Support | Peptides | BHRT | Colorado | AZ | NJ AOD 9604 with tirzepatide: the

Expert Administration: Professional B12 injections are administered by trained healthcare providers with experience with proper injection techniques, which reduces the risk of complications

Your clinician or lab can advise whether anything should be paused before blood work

Cartilage and Tissue Remodeling Models In addition to metabolic research, AOD 9604 has been explored in preclinical models of cartilage biology and tissue remodeling

Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy